A retrospective observational study investigating efficacy of sofosbuvir/ledipasvir therapy without ribavirin in patients with hepatitis C recurrence post liver transplant.

Trial Profile

A retrospective observational study investigating efficacy of sofosbuvir/ledipasvir therapy without ribavirin in patients with hepatitis C recurrence post liver transplant.

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Oct 2016

At a glance

  • Drugs Ledipasvir/sofosbuvir (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Oct 2016 New trial record
    • 14 Sep 2016 Primary endpoint (Sustained virologic response at 12 weeks) has been met, according to results published in the Transplantation.
    • 14 Sep 2016 Results published in the Transplantation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top